{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:54:29Z","timestamp":1765886069095},"reference-count":61,"publisher":"King Faisal Specialist Hospital and Research Centre","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Saudi Medicine"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.5144\/0256-4947.2015.95","type":"journal-article","created":{"date-parts":[[2017,3,25]],"date-time":"2017-03-25T10:32:49Z","timestamp":1490437969000},"page":"95-106","source":"Crossref","is-referenced-by-count":13,"title":["Prophylaxis and treatment of venous thromboembolism in patients with cancer: the Saudi clinical practice guideline"],"prefix":"10.5144","volume":"35","author":[{"given":"Fahad","family":"Al-Hameed","sequence":"first","affiliation":[{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Intensive Care Department, King Abdulaziz Medical City, NGHA, Jeddah, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan M","family":"Al-Dorzi","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Intensive Care Department, King Abdulaziz Medical City, NGHA, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulkarim","family":"Al Momen","sequence":"additional","affiliation":[{"name":"Department of Hematology, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farjah","family":"Algahtani","sequence":"additional","affiliation":[{"name":"Department of Hematology, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hazzaa","family":"Al Zahrani","sequence":"additional","affiliation":[{"name":"Department of Hematology, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Al Saleh","sequence":"additional","affiliation":[{"name":"Department of Hematology, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Al Sheef","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Fahad Medical City, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek","family":"Owaidah","sequence":"additional","affiliation":[{"name":"Department of Hematology, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waleed","family":"Alhazzani","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, Canada"},{"name":"Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Neumann","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, Canada"},{"name":"Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojtek","family":"Wiercioch","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Brozek","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, Canada"},{"name":"Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Sch\u00fcnemann","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, Canada"},{"name":"Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elie A.","family":"Akl","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada"},{"name":"Department of Internal Medicine, American University of Beirut, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3134","reference":[{"issue":"9828","key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(11)61904-1","article-title":"Pulmonary embolism and deep vein thrombosis","volume":"379","author":"Goldhaber SZ","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom JW","year":"2005","journal-title":"Jama"},{"issue":"1","key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000093551","article-title":"Mechanisms of cancer-induced thrombosis in cancer","volume":"35","author":"Rickles FR","year":"2006","journal-title":"Pathophysiol Haemost Thromb"},{"issue":"2","key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0049-3848(14)50007-2","article-title":"Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS)","volume":"133","author":"Konigsbrugge O","year":"2014","journal-title":"Thromb Res"},{"issue":"14","key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1002\/cncr.26597","article-title":"Risk assessment models for cancer-associated venous thromboembolism","volume":"118","author":"Dutia M","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1378\/chest.09-3081","article-title":"Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators","volume":"139","author":"Decousus H","year":"2011","journal-title":"Chest"},{"key":"e_1_3_2_8_2","unstructured":"Al-Eid HSQ Manuel A. Cancer Incidence Report Saudi Arabia 2010 Riyadh . 2014. Available from: www.chs.gov.sa."},{"issue":"5","key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/ijc.27711","article-title":"Global estimates of cancer prevalence for 27 sites in the adult population in 2008","volume":"132","author":"Bray F","year":"2013","journal-title":"Int J Cancer"},{"issue":"4","key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.7314\/APJCP.2012.13.4.1311","article-title":"Frequency, clinical pattern and outcome of thrombosis in cancer patients in Saudi Arabia","volume":"13","author":"Aleem A","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"e_1_3_2_11_2","volume-title":"Methodology for the Development of the Ministry of Health of Saudi Arabia and McMaster University Clinical Practice Guidelines","author":"McMaster University Guideline Working Group","year":"2014"},{"key":"e_1_3_2_12_2","first-page":"CD006652","article-title":"Parenteral anticoagulation in ambulatory patients with cancer","volume":"12","author":"Akl EA","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_13_2","first-page":"CD006466","article-title":"Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation","volume":"7","author":"Akl EA","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_14_2","first-page":"CD006466","article-title":"Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation","volume":"6","author":"Akl EA","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_15_2","first-page":"CD006468","article-title":"Anticoagulation for people with cancer and central venous catheters","volume":"10","author":"Akl EA","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_16_2","first-page":"CD006649","article-title":"Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer","volume":"6","author":"Akl EA","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_17_2","first-page":"CD006650","article-title":"Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer","volume":"7","author":"Akl EA","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_18_2","unstructured":"World Health Organization. WHO Handbook for Guideline Development World Health Organization; 2012. [cited 2014 February 7]. Available from: http:\/\/apps.who.int\/iris\/bitstream\/10665\/75146\/1\/9789241548441_eng.pdf."},{"issue":"4","key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt G","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem H","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","article-title":"GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations","volume":"66","author":"Andrews J","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"e_1_3_2_22_2","first-page":"CD006652","article-title":"Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation","author":"Akl EA","year":"2011","journal-title":"The Cochrane database of systematic reviews"},{"issue":"6","key":"e_1_3_2_23_2","first-page":"CD006466","article-title":"Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation","author":"Akl EA","year":"2011","journal-title":"The Cochrane database of systematic reviews"},{"issue":"4","key":"e_1_3_2_24_2","first-page":"CD006468","article-title":"Anticoagulation for patients with cancer and central venous catheters","author":"Akl EA","year":"2011","journal-title":"The Cochrane database of systematic reviews"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006649.pub5"},{"issue":"6","key":"e_1_3_2_26_2","first-page":"CD006650","article-title":"Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer","author":"Akl EA","year":"2011","journal-title":"The Cochrane database of systematic reviews"},{"issue":"7","key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"Agnelli G","year":"2012","journal-title":"New England Jour Med"},{"issue":"9","key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ejca.2011.10.017","article-title":"Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer","volume":"48","author":"Maraveyas A","year":"2012","journal-title":"Eur J Cancer"},{"issue":"15","key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1200\/JCO.2010.31.9293","article-title":"Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer","volume":"29","author":"van Doormaal FF","year":"2011","journal-title":"J Clin Oncol: official journal of the ASCO"},{"issue":"7","key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.6004\/jnccn.2011.0064","article-title":"Risk assessment and prophylaxis for VTE in cancer patients","volume":"9","author":"Khorana AA","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1538-7836.2012.04693.x","article-title":"A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer","volume":"10","author":"Levine MN","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"1","key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00280-013-2169-y","article-title":"Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study","volume":"72","author":"Lavau-Denes S","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1016\/j.ejim.2013.08.439","article-title":"Impact of an out-patient based strategy for the management of acute deep venous thrombosis in Saudi Arabia","volume":"24","author":"Salih A","year":"2013","journal-title":"Eur J Inter Med"},{"issue":"2","key":"e_1_3_2_34_2","first-page":"165","article-title":"Hospital versus home treatment of deep vein thrombosis in a tertiary care hospital in Saudi Arabia: Are we ready?","volume":"21","author":"Algahtani F","year":"2013","journal-title":"SPJ :the official publication of the Saudi Pharmaceutical Society"},{"issue":"1","key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1080\/02813430310003543","article-title":"Deep venous thrombosis: a new task for primary health care. A randomised economic study of outpatient and inpatient treatment","volume":"22","author":"Backman K","year":"2004","journal-title":"Scand J Prim Health Care"},{"issue":"19","key":"e_1_3_2_36_2","first-page":"2298","article-title":"Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis","volume":"159","author":"O\u2019Brien B","year":"1999","journal-title":"Arch Intern Med"},{"issue":"1","key":"e_1_3_2_37_2","first-page":"S10","article-title":"Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation","volume":"8","author":"Huse DM","year":"2002","journal-title":"Am J Manag Care"},{"issue":"1","key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1378\/chest.122.1.108","article-title":"Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin","volume":"122","author":"Spyropoulos AC","year":"2002","journal-title":"Chest"},{"issue":"19","key":"e_1_3_2_39_2","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1001\/archinte.160.19.2926","article-title":"Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization","volume":"160","author":"Tillman DJ","year":"2000","journal-title":"Arch Intern Med"},{"issue":"8","key":"e_1_3_2_40_2","first-page":"931","article-title":"Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis","volume":"159","author":"Rodger M","year":"1998","journal-title":"CMAJ"},{"issue":"2","key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1055\/s-0037-1614975","article-title":"Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis--an economic evaluation. TASMAN Study Group","volume":"79","author":"van den Belt AG","year":"1998","journal-title":"Thromb Haemost"},{"issue":"1","key":"e_1_3_2_42_2","first-page":"86","article-title":"Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial","volume":"104","author":"van Doormaal FF","year":"2010","journal-title":"Thromb Haemost"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1177\/1076029606293692"},{"issue":"1","key":"e_1_3_2_44_2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.amjmed.2006.03.030","article-title":"Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms","volume":"120","author":"Hull RD","year":"2007","journal-title":"Am J Med"},{"issue":"8","key":"e_1_3_2_45_2","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.amjmed.2008.12.023","article-title":"Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome","volume":"122","author":"Hull RD","year":"2009","journal-title":"Am J Med"},{"issue":"2","key":"e_1_3_2_46_2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee AY","year":"2003","journal-title":"N Engl J Med"},{"key":"e_1_3_2_47_2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1055\/s-0037-1614412","article-title":"Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis","volume":"81","author":"Lopaciuk S","year":"1999","journal-title":"Thromb Haemost"},{"issue":"1","key":"e_1_3_2_48_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1067\/mva.2001.109336","article-title":"Low molecular weight heparin versus oral anticoagulants in the long- term treatment of deep venous thrombosis","volume":"33","author":"Lopez-Beret P","year":"2001","journal-title":"J Vasc Surg"},{"issue":"15","key":"e_1_3_2_49_2","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study","volume":"162","author":"Meyer G","year":"2002","journal-title":"Archiv Int Med[AUTHOR: Please check the journal abbreviation for correctness]"},{"issue":"3","key":"e_1_3_2_50_2","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ejvs.2008.11.030","article-title":"A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis","volume":"37","author":"Romera A","year":"2009","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"12","key":"e_1_3_2_51_2","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","article-title":"Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer","volume":"119","author":"Hull RD","year":"2006","journal-title":"Am J Med"},{"issue":"2","key":"e_1_3_2_52_2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/s-0038-1648837","article-title":"Low molecular weight heparin versus warfarin the prevention of recurrence after deep vein thrombosis","volume":"72","author":"Pini M","year":"1994","journal-title":"Thromb Haemost"},{"key":"e_1_3_2_53_2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s002689900081","article-title":"Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: A randomized trial","volume":"20","author":"Das SK","year":"1996","journal-title":"World J Surg"},{"issue":"2","key":"e_1_3_2_54_2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0741-5214(99)70139-4","article-title":"Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis","volume":"30","author":"Gonzalez-Fajardo JA","year":"1999","journal-title":"J Vasc Surg"},{"issue":"4","key":"e_1_3_2_55_2","first-page":"559","article-title":"Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial","volume":"84","author":"Veiga F","year":"2000","journal-title":"Thromb Haemost"},{"issue":"4","key":"e_1_3_2_56_2","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1055\/s-0037-1613574","article-title":"Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis","volume":"89","author":"Kakkar V","year":"2003","journal-title":"Thromb Haemost"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.1283"},{"issue":"6","key":"e_1_3_2_58_2","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1200\/JCO.2014.59.7351","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014","volume":"33","author":"Lyman GH","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"e_1_3_2_59_2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/jth.12070","article-title":"International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"11","author":"Farge D","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"2","key":"e_1_3_2_60_2","doi-asserted-by":"crossref","first-page":"e195S","DOI":"10.1378\/chest.11-2296","article-title":"Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kahn SR","year":"2012","journal-title":"Chest"},{"issue":"2","key":"e_1_3_2_61_2","doi-asserted-by":"crossref","first-page":"e227S","DOI":"10.1378\/chest.11-2297","article-title":"Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Gould MK","year":"2012","journal-title":"Chest"},{"issue":"2","key":"e_1_3_2_62_2","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kearon C","year":"2012","journal-title":"Chest"}],"container-title":["Annals of Saudi Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.annsaudimed.net\/index.php\/vol35\/vol35iss2\/796.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T10:51:15Z","timestamp":1579171875000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.annsaudimed.net\/doi\/10.5144\/0256-4947.2015.95"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.5144\/0256-4947.2015.95"],"URL":"https:\/\/doi.org\/10.5144\/0256-4947.2015.95","relation":{},"ISSN":["0256-4947","0975-4466"],"issn-type":[{"value":"0256-4947","type":"print"},{"value":"0975-4466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}